Core Viewpoint - The financial advisor, China Merchants Securities Co., Ltd., has verified the detailed equity change report of Renfu Pharmaceutical Group Co., Ltd., confirming that the disclosed content and format comply with regulations and that there are no false records, misleading statements, or significant omissions [1][6][9]. Summary by Sections Financial Advisor's Verification - The financial advisor conducted a thorough review of the detailed equity change report and confirmed that the information provided by the disclosing party is true, accurate, complete, and timely, with no significant omissions or misleading statements [2][6]. - The advisor's opinion is based on the assumption that the disclosing party has fully and timely fulfilled its obligations related to the transaction [2][3]. Disclosing Party's Information - The disclosing party, China Merchants Life Science (Wuhan) Co., Ltd., has a registered capital of 200 million RMB and is involved in medical research and development [7][12]. - The equity structure of the disclosing party shows that it is wholly owned by China Merchants Innovation Technology (Group) Co., Ltd. [12][15]. Equity Change Details - Following the signing of the agreement, the disclosing party and its affiliates will collectively hold 429,276,816 shares of the listed company, accounting for 26.30% of the total share capital [5][9]. - The trust plan "Chun Ni 1" was established to execute the restructuring plan of the company "Wuhan Contemporary Technology Industry Group Co., Ltd." and involves the transfer of 11.70% of Renfu Pharmaceutical's shares [9][10]. Financial Performance of Related Entities - Wuhan High-Tech State-owned Holding Group Co., Ltd. reported total assets of 994.47 billion RMB, total liabilities of 707.50 billion RMB, and a net profit of 1.54 billion RMB for the year 2024 [23][24]. - The financial data for China Merchants Group shows total assets of 28,751.03 billion RMB and a net profit of 786.16 million RMB for the year 2024 [25].

广济药业（000952）公告，近日收到国家卫生健康委员会《行政许可审查结论通知书》，公司提交的 2'-岩藻糖基乳糖行政许可申请已通过审查并公告。2'-岩藻糖基乳糖为母乳中含量丰富的低聚糖，具有 调节肠道菌群、促进大脑发育和提升免疫力等功能，已列入食品营养强化剂，允许用于调制乳粉、婴儿 配方食品等。公司自主研发的2'-岩藻糖基乳糖正式通过审批，符合国家相关技术审查标准，为公司推 进该产品产业化奠定基础。 ...

+0.03(+0.52%) +0.09(+0.74%) -0.05(-0.57%) 光大银行 2623.40亿市值 9.22亿成交额 4.44 +0.01(+0.23%) 得經 中国平安 中国太保 中国人保 明 3798.84亿市值 3619.17亿市值 10403.51亿市值 47.27亿成交额 8.03亿成交额 15.55亿成交额 57.13 8.59 37.62 +0.52(+1.40%) +1.23(+2.20%) +0.07(+0.82%) 酿酒行业 贵州茅台 山西汾酒 五粮液 17919.66亿市值 2178.12亿市值 4758.08亿市值 55.03亿成交额 19.84亿成交额 12.73亿成交额 1426.50 178.54 122.58 +7.62(+0.54%) +0.26(+0.15%) +0.98(+0.81%) 半导体 北方华创 寒武纪-U 海光信息 HYGON 2380.06亿市值 2190.06亿市值 3140.41亿市值 15.03亿成交额 45.22亿成交额 14.81亿成交额 135.11 523.50 329.83 -1.32(-0.40%) -11.50(-2.15% ...

Group 1: Market Overview - The FTSE China A50 Index components showed a positive trend with insurance, oil, and securities sectors rising significantly, while the banking sector also performed well [1][6]. Group 2: Sector Performance - The insurance sector, including companies like China Life and Ping An, saw increases in market capitalization, with China Life at 1,387.12 billion and Ping An at 1,036.22 billion, reflecting gains of 2.05% and 2.04% respectively [3]. - The oil sector, represented by Sinopec and PetroChina, also experienced growth, with Sinopec's market cap at 698.73 billion and PetroChina at 1,588.62 billion, both showing positive changes of 1.17% and 1.41% respectively [3]. - The semiconductor industry, including Northern Huachuang and Cambrian, faced slight declines, with Northern Huachuang down by 1.43% [3]. - The beverage sector, particularly Kweichow Moutai, reported a market cap of 1,780.16 billion, with a minor decrease of 0.13% [3]. Group 3: Trading Volume - Trading volumes varied across sectors, with the insurance sector leading with a total trading volume of 24.01 billion for Ping An, while the semiconductor sector had lower volumes, with Northern Huachuang at 9.73 billion [3][4]. - The automotive sector, represented by BYD, had a significant trading volume of 47.62 billion, indicating strong investor interest [3].

Report Summary 1. Report Industry Investment Rating - No information provided regarding the industry investment rating. 2. Core Viewpoints - The report focuses on the in - depth investigation of Lianhuan Pharmaceutical, covering the company's strategic positioning, responses to challenges, and future development plans [26][28][30]. 3. Summary by Directory 3.1. Research Basic Situation - The research object is Lianhuan Pharmaceutical, belonging to the chemical pharmaceutical industry. The reception time was July 9, 2025. The company's reception staff included the chairman, board secretary, general manager, and other key personnel [16]. 3.2. Detailed Research Institutions - The institutions participating in the research include Jiangsu Securities Industry Association, China CITIC Bank, CITIC Construction Securities, Huabao Securities, Yida Capital, Xianghe Investment, Jiazhi Private Equity, Junzilan Capital, Yuanfang Capital, Jintou Assets, Yipin Assets, Deep Vision Technology, and Yangzhou Newspaper Group [17][18]. 3.3. Proportion of Research Institutions - Other types of institutions account for 54%, asset management companies 23%, securities companies 15%, and joint - stock commercial banks 8% [20][21][22]. 3.4. Main Content Information - **Event Background**: On July 8, 2025, CITIC Construction Securities Yangzhou Jiangyang Middle Road Securities Business Department, together with the Jiangsu Securities Industry Association, organized an event to visit Lianhuan Pharmaceutical [25]. - **Strategic Positioning and Core Competitiveness**: The company adheres to the "innovation - driven development" strategy. In 2024, the R & D investment was about 277 million yuan. It focuses on innovation drugs, high - end preparations, and large - variety generic drugs in R & D, promotes business model innovation in sales, and improves quality stability through intelligent transformation in production. It has passed the FDA on - site inspection twice and won the "Advanced - level Intelligent Factory in Jiangsu Province" title [26]. - **Impact of Centralized Procurement and Countermeasures**: The company recognizes the strategic value of centralized procurement policies and has established a dynamic policy research mechanism. It copes with challenges by optimizing product structure, accelerating innovation R & D, and deepening hospital - enterprise cooperation [28]. - **Logic and Synergy of Mergers and Acquisitions**: The acquisition of Changle Pharmaceutical aims at strategic synergy, layout optimization, production line complementarity, and cost advantages. The acquisition of Longyi Pharmaceutical is to expand CSO business and improve the pharmaceutical circulation layout. After the acquisitions, the company achieves all - round synergy through various measures [28]. - **Market Value Management Plan**: As a state - owned enterprise, the company attaches great importance to market value management. It is drafting a special market value management plan, focusing on R & D investment, market expansion, capital operation, and investor relationship management, and has maintained a 30% annual dividend ratio [29][30]. - **Future Development Strategy**: The company will continue to adhere to a market - oriented and innovation - centered development strategy, optimize product structure, expand the market, improve management efficiency, and carry out strategic investments and cooperation in a timely manner [30].

Core Viewpoint - *ST Shuangcheng has no current plans to acquire a semiconductor company and is actively taking measures to mitigate the risk of delisting by enhancing its marketing strategies and international sales efforts [1] Group 1: Marketing and Sales Strategies - The company is adapting to new national medical insurance and procurement policies to increase sales volume of existing products [1] - Efforts are being made to enhance international sales, particularly following the approval of its injectable paclitaxel (albumin-bound) for legal sale in the U.S., which boosts market competitiveness [1] Group 2: Export and Production - The company aims to maintain existing customer orders in its peptide business while expanding its customer base and utilizing the increased purification capacity of its expanded peptide workshop [1] - Active promotion of pending product approvals and ANDA submissions in the U.S., Canada, and other countries is underway, alongside efforts to secure more CDMO projects and technical collaborations [1] Group 3: CMO Cooperation and Cost Control - The company is leveraging its GMP capabilities in sterile products to pursue external CMO collaborations, particularly with major clients [1] - Continuous cost control measures are being implemented, focusing on optimizing personnel configuration, enhancing efficiency, ensuring reasonable procurement, and monitoring expense rationality [1]

Core Viewpoint - Hainan Haiyao's subsidiary has received approval for the injectable drug Cefoperazone Sodium, which is expected to enhance market competitiveness and positively impact the company's performance [1] Company Summary - Hainan Haiyao's wholly-owned subsidiary, Haikou Pharmaceutical Factory, has been granted a drug supplement approval notice by the National Medical Products Administration for the injectable drug Cefoperazone Sodium [1] - The drug has passed the consistency evaluation of quality and efficacy for generic drugs, which is beneficial for the company's market position [1] Industry Summary - Cefoperazone Sodium is a third-generation broad-spectrum semi-synthetic cephalosporin antibiotic, effective against various infections including lower respiratory tract infections, urinary tract infections, and sepsis [1] - The approval of this drug aligns with the industry's trend towards enhancing the quality and efficacy of generic medications, which is crucial for maintaining competitiveness in the pharmaceutical market [1]

Group 1 - Morning Light Biological expects a net profit of 202.0 million to 232.0 million yuan for the first half of 2025, representing a year-on-year increase of 102.33% to 132.38% [1] - Northern Rare Earth anticipates a net profit of 900.0 million to 960.0 million yuan for the first half of 2025, with a significant year-on-year growth of 1882.54% to 2014.71% [1] - Youfa Group forecasts a net profit of 277.0 million to 307.0 million yuan for the first half of 2025, reflecting a year-on-year increase of 151.69% to 178.93% [1] Group 2 - Torch Electronics projects a net profit of approximately 247.0 million to 280.0 million yuan for the first half of 2025, indicating a year-on-year growth of 50.36% to 70.45% [3] - Zhiwei Intelligent expects a net profit of 91.98 million to 112.43 million yuan for the first half of 2025, with a year-on-year increase of 62.85% to 99.06% [4] - Youhao Group anticipates a net profit of 12.0 million yuan for the first half of 2025, representing a year-on-year growth of 51% [5] Group 3 - Nami Technology expects a net profit of 61.0 million to 73.0 million yuan for the first half of 2025, with a year-on-year increase of 35% to 62% [7] - Xinda Co. forecasts a net profit of 130.0 million to 150.0 million yuan for the first half of 2025, reflecting a substantial year-on-year growth of 2443.43% to 2834.73% [8] Group 4 - Shaanxi Coal Industry reported a coal production of 14.36 million tons in June, a year-on-year decrease of 5.07% [9] - Huanxu Electronics announced a consolidated revenue of 4.587 billion yuan in June, a year-on-year decline of 1.23% [10] Group 5 - Huadian International successfully issued 2.0 billion yuan in medium-term notes with a maturity of 3+N years and a coupon rate of 1.89% [20] - Zhongmin Energy reported a total power generation of 1.405 billion kilowatt-hours in the first half of 2025, a year-on-year decrease of 0.89% [20] Group 6 - Huaxia Biotech passed the FDA inspection with zero deficiencies, covering six major systems [21] - Ruikeda's application for convertible bond issuance has been accepted by the Shanghai Stock Exchange [22] Group 7 - Dafu Technology plans to invest no more than 100 million yuan in Anhui Yunta [42] - Tongda Co. won a bid for a project valued at 180.3 million yuan from the Southern Power Grid [46]

Core Viewpoint - The company has announced an adjustment to the maximum repurchase price of its shares following the implementation of its 2024 annual profit distribution plan, reducing the price from RMB 14 to RMB 13.90 per share [1][2][4] Summary by Sections 1. Share Repurchase Basic Information - The company plans to repurchase its shares using its own and/or raised funds through centralized bidding, with a total repurchase amount between RMB 50 million and RMB 100 million [1] - The repurchase price was initially set at a maximum of RMB 14 per share, with a repurchase period of 12 months starting from the board's approval date [1] 2. Reasons for Adjusting the Repurchase Price Cap - The adjustment follows the approval of the 2024 annual profit distribution plan, which includes a cash dividend of RMB 0.10 per share, totaling RMB 82,829,774.50 [2][3] - The record date for the dividend distribution is July 16, 2025, and the ex-dividend date is July 17, 2025 [2] 3. Details of the Price Adjustment - The new maximum repurchase price is calculated as follows: (previous maximum price - cash dividend) / (1 + change in circulating shares ratio) [2] - The cash dividend per share is approximately RMB 0.0998, and since there is no change in circulating shares, the new maximum repurchase price is approximately RMB 13.90 [3] 4. Other Matters - Other aspects of the share repurchase plan remain unchanged, and the company will proceed with the repurchase plan in accordance with relevant laws and regulations [4]

Market Overview - The FTSE China A50 Index components showed varied performance, with the liquor sector rising throughout the day while the semiconductor sector experienced a decline in the afternoon [1] Insurance Sector - China Life Insurance, China Pacific Insurance, and Ping An Insurance had market capitalizations of CNY 376.78 billion, CNY 356.91 billion, and CNY 1,017.95 billion respectively, with trading volumes of CNY 0.75 billion, CNY 2.22 billion, and CNY 0.84 billion [3] - The stock prices changed as follows: China Life Insurance decreased by CNY 0.73 (-1.93%), China Pacific Insurance decreased by CNY 0.55 (-0.97%), and Ping An Insurance decreased by CNY 0.14 (-1.62%) [3] Liquor Industry - Kweichow Moutai, Shanxi Fenjiu, and Wuliangye had market capitalizations of CNY 1,782.39 billion, CNY 217.50 billion, and CNY 472.00 billion respectively, with trading volumes of CNY 3.95 billion, CNY 2.00 billion, and CNY 2.48 billion [3] - Stock price changes included Kweichow Moutai increasing by CNY 2.38 (+1.35%), Shanxi Fenjiu increasing by CNY 0.82 (+0.68%), and Wuliangye increasing by CNY 2.77 (+0.20%) [3] Semiconductor Sector - Northern Huachuang, Cambricon Technologies, and Hygon had market capitalizations of CNY 238.96 billion, CNY 223.82 billion, and CNY 314.69 billion respectively, with trading volumes of CNY 1.47 billion, CNY 1.23 billion, and CNY 2.64 billion [3] - The stock prices changed as follows: Northern Huachuang decreased by CNY 7.77 (-1.43%), Cambricon Technologies decreased by CNY 1.51 (-1.10%), and Hygon decreased by CNY 2.82 (-0.84%) [3] Automotive Sector - BYD, Great Wall Motors, and Beijing-Shanghai High-Speed Railway had market capitalizations of CNY 187.27 billion, CNY 1,790.16 billion, and CNY 280.83 billion respectively, with trading volumes of CNY 3.97 billion, CNY 0.31 billion, and CNY 0.56 billion [3] - Stock price changes included BYD decreasing by CNY 1.08 (-0.33%), Great Wall Motors decreasing by CNY 0.08 (-0.36%), and Beijing-Shanghai High-Speed Railway increasing by CNY 0.03 (+0.53%) [3] Shipping and Oil Sector - COSCO Shipping Holdings, Sinopec, and PetroChina had market capitalizations of CNY 235.91 billion, CNY 688.67 billion, and CNY 1,570.32 billion respectively, with trading volumes of CNY 0.77 billion, CNY 1.08 billion, and CNY 0.76 billion [3] - The stock prices changed as follows: COSCO Shipping Holdings remained unchanged, Sinopec decreased by CNY 0.09 (-0.59%), and PetroChina increased by CNY 0.01 (+0.12%) [3] Coal and Battery Sector - China Shenhua, Shaanxi Coal and Chemical Industry, and CATL had market capitalizations of CNY 185.95 billion, CNY 745.07 billion, and CNY 1,234.66 billion respectively, with trading volumes of CNY 0.79 billion, CNY 0.69 billion, and CNY 7.95 billion [3] - Stock price changes included China Shenhua increasing by CNY 7.49 (+2.84%), Shaanxi Coal and Chemical Industry decreasing by CNY 0.22 (-0.58%), and CATL increasing by CNY 0.03 (+0.16%) [3] Other Sectors - Various sectors such as food and beverage, electronics, and pharmaceuticals showed mixed performance in terms of market capitalization and stock price changes [4]